P. mirabilis-derived pore-forming haemolysin, HpmA drives intestinal alpha-synuclein aggregation in a mouse model of neurodegeneration.

Authors:
Huh E; Choi JG; Choi Y; Ju IG; Kim B and 10 more

Journal:
EBioMedicine

Publication Year: 2023

DOI:
10.1016/j.ebiom.2023.104887

PMCID:
PMC10709029

PMID:
37995468

Journal Information

Full Title: EBioMedicine

Abbreviation: EBioMedicine

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Genetics, Medical

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of interests EH, JGC, DHK and MSO are inventors with a provisional patent, “Method for diagnosing neurodegenerative disease using HpmA” that is licensed to MetaCen Therapeutics. MGP is a co-founder of MetaCen Therapeutics."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025